Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials
Analyses involving two large phase III trials investigating adjuvant IO treatment for resected melanoma demonstrate higher cure rates for both NIVO and IPI than placebo, with NIVO providing the highest cure rate. Similar cure rates were estimated for patients treated with IPI in both trials, despite staging and dosing differences.
Authors
- Georgia Yates (ORCID: https://orcid.org/0009-0006-9996-1961)
- J. Vanderpuye-Orgle (ORCID: https://orcid.org/0000-0002-4533-1298)
- Andriy Moshyk (ORCID: https://orcid.org/0000-0003-4895-7103)
- Peter Mohr (ORCID: https://orcid.org/0000-0002-7328-7407)
- Jeffrey S. Weber (ORCID: https://orcid.org/0000-0002-4962-2957)
- Mark R. Middleton (ORCID: https://orcid.org/0000-0003-0167-1685)
- Maurice Lobo (ORCID: https://orcid.org/0009-0008-4674-6744)
- Daniel Sharpe (ORCID: https://orcid.org/0000-0003-2079-2677)
- Murat Kurt (ORCID: https://orcid.org/0000-0001-8206-606X)
Institutions
- PAREXEL International (United Kingdom) (GB)
- University of Oxford (GB)
- Bristol-Myers Squibb (United States) (US)
- PAREXEL International (United States) (US)
- Elbe Kliniken Stade-Buxtehude (DE)
- NYU Langone’s Laura and Isaac Perlmutter Cancer Center
- New York University (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-10-08
- DOI
- https://doi.org/10.1200/jco.24.00237
- Citations
- 4
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.13